Market Intelligence, Clinical Progress, and High-Purity Reagents for GJA1-Targeted Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Connexin 43 (GJA1) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Connexin 43 / GJA1 Lentivirus Premade Particles Full-length human GJA1 ORF for stable cell line generation. Preserves native 4-pass transmembrane conformation. |
View GJA1 Products |
| Gene Delivery | GJA1 Promise-ORF / Lentivirus High-titer expression vectors for functional dye-coupling and electrophysiology assays. |
View GJA1 Products |
| Benchmark Ab | Anti-GJA1 Recombinant Antibody Sequence-verified positive control targeting the extracellular loops or C-terminus. |
View GJA1 Products |
| Validator | GJA1 siRNA Set Target-specific knockdown pool for specificity validation in phenotypic assays. |
View GJA1 Products |
| Related Target A | Connexin 40 / GJA5 Critical cardiac connexin homolog for selectivity counter-screening to prevent cardiotoxicity. |
View GJA5 Products |
| Related Target B | Pannexin 1 / PANX1 Non-junctional hemichannel target with overlapping ATP-release functions in inflammatory pathways. |
View PANX1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 4-Pass Transmembrane Protein | Lentivirus-driven stable cell line generation to preserve native hexameric connexon structures. |
| Subfamily Off-target Screening (GJA5/GJA4) | Sequence-verified GJA5 and GJA4 lentiviruses/plasmids available for cross-reactivity profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA sets included for target knockdown and specificity verification. |
Live Connexin 43 (GJA1) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Connexin 43 (GJA1) therapeutics is intensifying, with major players shifting focus from traditional small-molecule channel blockers to highly selective peptide mimetics and monoclonal antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise modulation of hemichannel opening versus gap junction intercellular communication (GJIC) to treat inflammatory, cardiac, and wound-healing pathologies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptides (e.g., αCT1) | FirstString Research | Wound Healing, Scar Reduction | Functional cell-based assays (Need high-titer GJA1 Lentivirus for stable reporter lines) |
| Small Molecules | Zealand Pharma | Cardiac Arrhythmia, Ischemia | Selectivity profiling (Need GJA5/GJA1 comparative overexpression panels) |
| Monoclonal Antibodies | Academic / Biotech Spin-offs | Oncology, Neuroinflammation | Extracellular loop binding assays (Need native conformation preservation via Lentivirus transduction) |